J&J abandons influenza A treatment programme for pimodivir after interim analysis

Phase III trial of this first-in-class non-nucleotide inhibitor of PB2 subunit of influenza A polymerase complex in hospitalized influenza A patients suggested that addition to standard of care (SOC) was “very unlikely” to show added benefit over SOC alone.


Biospace Inc.